Finally, to further extend our observations to a clinicopathologically relevant setting, we performed Kaplan–Meier survival analysis (http://kmplot.com/analysis/) of public data sets and found that higher ZNF516 or CtBP1 expression is associated with a better relapse-free survival of breast cancer patients, when the influence of systemic treatment, endocrine therapy, and chemotherapy were excluded (Fig. 9e). This evidence concerns the gene ZNF516 and breast carcinoma.